CSIMarket
 


Aclaris Therapeutics Inc   (ACRS)
Other Ticker:  
 

Cumulative Aclaris Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

ACRS's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ACRS Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 43.62 % 41.99 % 44.55 % 5.55 % -7.31 %
Y / Y Current Assets Growth -44.35 % -52.03 % -48.74 % -3.42 % 12.93 %
Working Capital Ratio for Trailing Twelve Months Period 5.83 7.61 10.03 12.69 12.95
Total Ranking # 286 # 418 # 319 # 265 # 283
Seq. Current Liabilities Growth 13.02 % 20.74 % 26.71 % -16.93 % 11.73 %
Seq. Current Assets Growth 4.7 % -7.42 % -27.89 % -20.38 % -9.75 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to increase in Current Liabilities in the IV. Quarter to $31 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 5.83 below Aclaris Therapeutics Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Aclaris Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about ACRS
Working Capital Ratio ACRS in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 103
Sector # 208
S&P 500 # 424


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
17.61 8.7 3.6
(Dec 31 2017)   (Mar 31 2020)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Zomedica Corp   15.94 
Pasithea Therapeutics Corp   15.80 
89bio Inc   15.56 
Verve Therapeutics Inc   15.30 
Immuneering Corporation  15.28 
Ovid Therapeutics Inc   15.05 
Cadrenal Therapeutics Inc   14.96 
Compass Pathways Plc  14.65 
Artelo Biosciences Inc   14.65 
Rani Therapeutics Holdings Inc   14.63 
Syndax Pharmaceuticals Inc   14.27 
Scpharmaceuticals Inc   14.25 
Viking Therapeutics Inc   13.94 
Cassava Sciences Inc  13.85 
Ideaya Biosciences Inc   13.84 
Immutep Limited  13.81 
Ocuphire Pharma Inc   13.74 
Cryoport inc   13.63 
Vanda Pharmaceuticals Inc   13.33 
Lipocine Inc   13.26 
Vistagen Therapeutics Inc   13.23 
Nkarta Inc   13.22 
Io Biotech Inc   13.19 
Larimar Therapeutics Inc   13.16 
Prothena Corporation Public Limited Company  13.14 
Olema Pharmaceuticals inc   13.10 
Atai Life Sciences N v   13.08 
Anaptysbio Inc   13.06 
Crinetics Pharmaceuticals Inc   12.99 
Oric Pharmaceuticals Inc   12.92 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com